New Science Ventures — 2018 Investments

1 investments dated 2018 · listed companies and verified rows first · show all

Cambridge Epigenetixcambridge-epigenetix.com 𝕏Apr 2018 · $88M

The company develops a 6-base sequencing platform (duet evoC) that simultaneously profiles methylation (5mC, 5hmC), genetic variants, and fragmentomics from a single cfDNA sample.

BiotechDeep TechHealthtechCambridge

Jason Mellad(Executive Officer, Director)inMartin Murphy(Director)Bobby Yerramilli-Rao(Co-founder)Somasundaram Subramaniam(Director)Timothy Rink(Director)Thomas Hulme(Director)

Co-investorsThird Point Ventures Ahren Innovation Capital GV (Google Ventures)Sequoia Capital Temasek Third Point

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.